Genetic Technologies Limited (GENE)

2,2230 -0,1270 (-5,40%) Al cierre: 04:00PM EDT

Genetic Technologies Limited

60-66 Hanover Street
Fitzroy, VIC 3065
Australia
61 3 8412 7000
https://genetype.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 60

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Simon Morriss	Chief Executive Officer	258,91k	N/A	N/A
Mr. Carl S. Stubbings BSc	Chief Commercial Officer	171,5k	N/A	N/A
Mr. Kevin Camilleri	Chief Executive Officer of EasyDNA	165,52k	N/A	N/A
Ms. Kathryn J. E. Andrews B.Com., C.P.A., M.A.I.C.D.	CFO & Company Secretary	N/A	N/A	1967
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA	Consultant	117,86k	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Gobierno corporativo

El ISS Governance QualityScore de Genetic Technologies Limited, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.